Status:
COMPLETED
Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)
Lead Sponsor:
Nucryst Pharmaceuticals
Conditions:
Atopic Dermatitis
Eczema
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Nanocrystalline silver (very small particles of silver) is the active ingredient in Acticoat dressings, which have been approved for the treatment of burns and other wounds. Silver has been used for d...
Eligibility Criteria
Inclusion
- Male or female, any race, 18 to 65 years of age.
- Females must be post-menopausal, surgically sterile, or if of child-bearing potential, not pregnant (confirmed by test) and using an adequate method of birth control.
- Subjects must have eczema that covers a minimum of 5% total body surface area.
- Subjects must agree not to use other eczema medications for the 6-week study treatment period.
- Subjects must not be enrolled in another investigational drug study.
- Subjects must not be allergic to silver or cocoa butter.
Exclusion
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
April 1 2004
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00076375
Start Date
November 1 2003
End Date
April 1 2004
Last Update
June 24 2005
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Radiant Research
Birmingham, Alabama, United States, 35209
2
Medical Affliated Research Centers, Inc.
Huntsville, Alabama, United States, 35801
3
National Jewish Medical & Research Center
Denver, Colorado, United States, 80206
4
nTouch Research
Washington D.C., District of Columbia, United States, 20037